Director, Pipeline and Portfolio Market Planning at Corcept Therapeutics

Redwood City, California, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

Proven ability to lead strategic planning initiatives across multiple therapeutic areas, integrating scientific, clinical, commercial, and regulatory perspectives
Deep understanding of the drug development process, spanning early through late-stage programs, with experience translating clinical insights into commercial strategy
Exceptional executive communication skills; adept at conveying insights and strategies to senior leadership through compelling storytelling
Strong market research and analytical acumen with the ability to translate data into compelling strategic recommendations
Skilled at operating effectively in a dynamic, matrixed environment, building alignment and influence

Responsibilities

Drive and influence program-level strategy initiatives to define product vision, optimize lifecycle value, and drive business impact
Provide physician, patient, and payer perspective in clinical strategy and new product planning
Design, implement, and continuously refine competitive intelligence and market analysis frameworks that proactively inform program decision-making
Independently lead integrated cross-functional teams, including Commercial, Medical, Development, and Research, to ensure alignment and strategic continuity across the product lifecycle
Develop, maintain, and communicate robust long-range revenue forecasts and valuation models to support program planning and resource allocation
Synthesize market research, competitive intelligence, and analytics into actionable insights to inform executive decision-making
Own the development and management of target product profiles (TPPs) for pipeline products, working with R&D teams to influence and support decisions
Lead asset assessments and contribute to business development diligence, guiding executive decision-making
Oversee and execute ad hoc cross-portfolio workstreams, including global expansion initiatives in partnership with Emerging Markets team
Model and promote Corcept’s key principles, collaborating effectively, embracing possibilities, following the data, and leading by doing, to build a culture of accountability, innovation, and trust

Skills

Strategic Planning

Portfolio Management

Market Analysis

Competitive Intelligence

Financial Forecasting

Indication Selection

Target Product Profile

Patient Journey Analysis

Product Positioning

Lifecycle Management

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free